1 Olszewska E,Wagner M,Bernal-Sprekelsen M,et al.Etiopathogenesis of cholesteatoma[J].Eur Arch Otorhinolaryngol,2004,261:6.

2 Bassiouny M,Badour N,Omran A,et al.Histopathological and immunohistochemical characteristics of acquired cholesteatoma in children and adults[J].Egypt J Ear Nose Throat Allied Sci,2012,13:7.

3 Klenke C,Janowski S,Borck D,et al.Identification of novel cholesteatoma-related gene expression signatures using fullgenome microarrays[J].PLoS One,2012,7:e52718.

4 Jin BJ,Min HJ,Jeong JH,et al.Expression of EGFR and microvessel density in middle ear cholesteatoma[J].Clin Exp Otorhinolaryngol,2011,4:67.

5 Palko E,Poliska S,Csakanyi Z,et al.The c-MYC protooncogene expression in cholesteatoma[J].Biomed Res Int,2014,2014:639896.

6 Huisman MA,De Heer E,Grote JJ.Survival signaling and terminal differentiation in cholesteatoma epithelium[J].Acta Otolaryngol,2007,127:424.

7 Yune TY,Byun JY.Expression of PTEN and phosphorylated Akt in human cholesteatoma epithelium[J].Acta Otolaryngol,2009,129:501.

8 Huisman MA,De Heer E,Grote JJ.Sustained extracellular signalregulated kinase1/2 mitogen-activated protein kinase signalling is related to increased p21expression in cholesteatoma epithelium[J].Acta Otolaryngol,2005,125:134.

9 Albino AP,Kimmelman CP,Parisier SC.Cholesteatoma:a molecular and cellular puzzle[J].Am J Otol,1998,19:7.

10 Maniu A,Harabagiu O,Perde Schrepler M,et al.Molecular biology of cholesteatoma[J].Rom J Morphol Embryol,2014,55:7.

11 James AL,Chadha NK,Papsin BC,et al.Pediatric cholesteatoma and variants in the gene encoding connexin 26[J].Laryngoscope,2010,120:183.

12 Choung YH,Park K,Kang SO,et al.Expression of the gap junction proteins connexin 26and connexin 43in human middle ear cholesteatoma[J].Acta Otolaryngol,2006,126:138.

13 Muller PA,Vousden KH,Norman JC.p53and its mutants in tumor cell migration and invasion[J].J Cell Biol,2011,192:209.

14 Huismsn MA,Heer ED,Grote JJ.Cholesteatoma epithelium is characterized by increased expression Ki-67,p53and p21,with minimal apoptosis[J].Acta Otolaryngol,2003,123:377.

15 Motamed M,Powe D,Kendall CK,et al.p53Expression and kerati-nocyte hyperproliferation in middle ear cholesteatoma[J].Clin Otlaryngol,2002,27:505.

16 Bartel DP.MicroRNAs:genomics,biogenesis,mechanism,and function[J].Cell,2004,116:281.

17 Friedland DR,Eernisse R,Erbe C,et al.Cholesteatomagrowth and proliferation:posttranscriptional regulation by microRNA-21[J].Otol Neurotol,2009,30:998.

18 Chen X,Qin Z.Post-transcriptional regulation by microrna-21and let-7amicroRNA in paediatric cholesteatoma[J].J Int Med Res,2011,39:2110.

19 Dornelles Cde C,da Costa SS,Meurer L,et al.Comparison of acquired cholesteatoma between pediatric and adult patients[J].Eur Arch Otorhinolaryngol,2009,266:1553.

20 Langevin SM,Christensen BC.Let-7micro RNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome:a systematic review and eta-analysis[J].Cancer Med,2014,3:1385.

21 Zhang W,Chen X,Qin Z.Micro RNAlet-7asuppresses the growth and invasion of cholesteatoma keratinocytes[J].Mol Med Rep,2015,11:2097.

22 Louw L.Acquired cholesteatoma:summary of the cascade of molecular events[J].J Laryngol Otol,2013,127:542.

23 Kupper TS,The activated keratinocyte:a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses[J].J Invest Dermatol,1990,94(6Suppl):146S.

24 Yetiser S,Satar B,Aydin N.Expression of epidermal growth factor,tumor necrosis factor-alpha,and interleukin-1alpha in chronic otitis media with or without cholesteatoma[J].Otol Neurotol,2002,23:647.

25 Yoshikawa M,Kojima H,Yaguchi Y,et al.Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin[J].PLoS One,2013,8:e66725.

26 Akimoto R,Pawankar R,Yagi T,et al.Acquired and congenital cholesteatoma:determination of tumor necrosis factor-alpha,intercellular adhesion molecule-1,interleukin-1-alpha and lymphocyte functional antigen-1in the inflammatory process[J].ORL J Otorhinolaryngol Relat Spec,2000,62:257.

27 Sudhoff H,Dazert S,Gonzales AM,et al.Angiogenesis and angiogenic growth factors in middle ear cholesteatoma[J].Am J Otol,2000,21:793.

28 Haruyama T,Furukawa M,Kusunoki T,et al.Expression of IL-17and its role in bone destruction in human middle ear cholesteatoma[J].ORL J Otorhinolaryngol Relat Spec,2010,72:325.

29 Welkoborsky H J.Current concepts of the pathogenesis of acquired middle ear cholesteatoma[J].Laryngorhinotologie,2011,90:38.

30 Kawai T,Matsuyama T,Hosokawa Y,et al.B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease[J].Am J Pathol,2006,169:987.

31 Peek FA,Huisman MA,Berckmans RJ,et al.Lipopolysaccharide concentration and bone resorption in cholesteatoma[J].Otol Neurotol,2003,24:709.

32 Bjarnsholt T.The role of bacterial biofilms in chronic infections[J].APMIS,2013,136(Suppl):1.

33 Lampikoski H,Aarnisalo AA,Jero J,et al.Mastoid biofilm in chronic otitis media[J].Otol Neurotol,2012,33:785.

34 Preciado DA.Biology of cholesteatoma:special considerations in pediatric patients[J].Int J Pediatr Otorhinolaryngol,2012,6:319.

35 Nguyen KH,Suzuki H,Ohbuchi T,et al.Possible participation of acidic pH in bone resorption in middle ear cholesteatoma[J].Laryngoscope,2014,124:245.